0000899243-20-008004.txt : 20200311 0000899243-20-008004.hdr.sgml : 20200311 20200311203123 ACCESSION NUMBER: 0000899243-20-008004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200310 FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAUSMAN DIANA CENTRAL INDEX KEY: 0001563992 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38068 FILM NUMBER: 20706946 MAIL ADDRESS: STREET 1: C/O ONCOTHYREON INC. STREET 2: 2601 FOURTH AVE, SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER NAME: FORMER CONFORMED NAME: HAUSMAN DIANE DATE OF NAME CHANGE: 20121207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zymeworks Inc. CENTRAL INDEX KEY: 0001403752 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 540-1385 WEST 8TH AVENUE CITY: Vancouver STATE: A1 ZIP: V6H 3V9 BUSINESS PHONE: (604) 678-1388 MAIL ADDRESS: STREET 1: 540-1385 WEST 8TH AVENUE CITY: Vancouver STATE: A1 ZIP: V6H 3V9 FORMER COMPANY: FORMER CONFORMED NAME: Zymeworks Inc DATE OF NAME CHANGE: 20070620 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-10 0 0001403752 Zymeworks Inc. ZYME 0001563992 HAUSMAN DIANA C/O ZYMEWORKS INC. 1385 WEST 8TH AVENUE, SUITE 540 VANCOUVER A1 V6H 3V9 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 35.20 2020-03-10 4 A 0 45000 0.00 A 2030-03-09 Common Shares 45000 45000 D Restricted Stock Unit 2020-03-10 4 A 0 7500 0.00 A Common Shares 7500 7500 D Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in three equal annual installments beginning on March 10, 2021. /s/ Daniel Dex, Attorney-in-Fact 2020-03-11